Literature DB >> 33185999

Brief Report: Accuracy of FIB-4 for Cirrhosis in People Living With HIV and Hepatocellular Carcinoma.

Jessie Torgersen1,2, Michael J Kallan2, Dena M Carbonari2, Lesley S Park3, Rajni L Mehta4,5, Kathryn D'Addeo4,5, Janet P Tate4,5, Joseph K Lim4,5, Matthew Bidwell Goetz6, Maria C Rodriguez-Barradas7, Norbert Bräu8, Sheldon T Brown8, Tamar H Taddei4,5, Amy C Justice4,5, Vincent Lo Re1,2.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) may develop in the absence of cirrhosis in HIV, and determining how often this occurs can provide insights into mechanisms of carcinogenesis. Studies evaluating the prevalence of cirrhosis in the setting of HCC among people living with HIV (PLWH) often rely on noninvasive markers, such as the Fibrosis-4 Index for Hepatic Fibrosis (FIB-4). However, the accuracy of FIB-4 for cirrhosis in the setting of HCC has not been determined among PLWH.
METHODS: We conducted a cross-sectional study among PLWH in the Veterans Aging Cohort Study with VA cancer registry-confirmed HCC diagnosed between 1999 and 2015. FIB-4 was calculated using the age, alanine aminotransferase, aspartate aminotransferase, and platelet count obtained closest to, but within 1 year before, HCC diagnosis. Medical records were reviewed within 1 year before HCC diagnosis to determine the cirrhosis status. We evaluated the area under the receiver-operating characteristic curve and performance characteristics of FIB-4 for confirmed cirrhosis.
RESULTS: Incident HCC was diagnosed in 302 PLWH. After medical record review, 203 (67.2%, 95% confidence interval: 61.6% to 72.5%) had evidence of cirrhosis. FIB-4 identified patients with cirrhosis with an area under the receiver-operating characteristic curve of 0.67 (95% confidence interval: 0.60 to 0.73). FIB-4 scores >5.0 had a positive predictive value >80% and specificity of >77%, negative predictive value of <41%, and sensitivity of <45%.
CONCLUSION: The accuracy of FIB-4 for cirrhosis in the setting of HIV and HCC is modest and may result in misclassification of cirrhosis in this population.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33185999      PMCID: PMC8353543          DOI: 10.1097/QAI.0000000000002510

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  25 in total

1.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.

Authors:  Richard K Sterling; Eduardo Lissen; Nathan Clumeck; Ricard Sola; Mendes Cassia Correa; Julio Montaner; Mark S Sulkowski; Francesca J Torriani; Doug T Dieterich; David L Thomas; Diethelm Messinger; Mark Nelson
Journal:  Hepatology       Date:  2006-06       Impact factor: 17.425

2.  The risk of hepatocellular carcinoma among individuals with acquired immunodeficiency syndrome in the United States.

Authors:  Vikrant V Sahasrabuddhe; Meredith S Shiels; Katherine A McGlynn; Eric A Engels
Journal:  Cancer       Date:  2012-06-26       Impact factor: 6.860

3.  Differences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma.

Authors:  Jessie Torgersen; Tamar H Taddei; Lesley S Park; Dena M Carbonari; Michael J Kallan; Kisha Mitchell Richards; Xuchen Zhang; Darshana Jhala; Norbert Bräu; Robert Homer; Kathryn D'Addeo; Rajni Mehta; Melissa Skanderson; Farah Kidwai-Khan; Amy C Justice; Vincent Lo Re
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-10-01       Impact factor: 4.254

4.  Validating smoking data from the Veteran's Affairs Health Factors dataset, an electronic data source.

Authors:  Kathleen A McGinnis; Cynthia A Brandt; Melissa Skanderson; Amy C Justice; Shahida Shahrir; Adeel A Butt; Sheldon T Brown; Matthew S Freiberg; Cynthia L Gibert; Matthew Bidwell Goetz; Joon Woo Kim; Margaret A Pisani; David Rimland; Maria C Rodriguez-Barradas; Jason J Sico; Hilary A Tindle; Kristina Crothers
Journal:  Nicotine Tob Res       Date:  2011-09-12       Impact factor: 4.244

Review 5.  The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma.

Authors:  Chandan Sanghera; Jhia J Teh; David J Pinato
Journal:  Liver Int       Date:  2019-09-18       Impact factor: 5.828

6.  Liver fibrosis progression in hepatitis C virus infection after seroconversion.

Authors:  Adeel A Butt; Peng Yan; Vincent Lo Re; David Rimland; Matthew B Goetz; David Leaf; Matthew S Freiberg; Marina B Klein; Amy C Justice; Kenneth E Sherman
Journal:  JAMA Intern Med       Date:  2015-02       Impact factor: 21.873

7.  Hepatocellular carcinoma in noncirrhotic livers is associated with steatosis rather than steatohepatitis: potential implications for pathogenesis.

Authors:  Suzanne van Meer; Karel J van Erpecum; Dave Sprengers; Heinz-Josef Klümpen; Peter L M Jansen; Jan N M Ijzermans; Peter D Siersema; Robert A de Man; Joanne Verheij
Journal:  Eur J Gastroenterol Hepatol       Date:  2016-08       Impact factor: 2.566

8.  HIV infection and the risk of diabetes mellitus.

Authors:  Adeel A Butt; Kathleen McGinnis; Maria C Rodriguez-Barradas; Stephen Crystal; Michael Simberkoff; Matthew Bidwell Goetz; David Leaf; Amy C Justice
Journal:  AIDS       Date:  2009-06-19       Impact factor: 4.177

Review 9.  Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program.

Authors:  Guadalupe Garcia-Tsao; Joseph K Lim; Joseph Lim
Journal:  Am J Gastroenterol       Date:  2009-05-19       Impact factor: 10.864

10.  Current noninvasive liver reserve models do not predict histological fibrosis severity in hepatocellular carcinoma.

Authors:  Shu-Yein Ho; Po-Hong Liu; Chia-Yang Hsu; Cheng-Yuan Hsia; Chien-Wei Su; Yi-Jhen He; Yun-Hsuan Lee; Yi-Hsiang Huang; Ming-Chih Hou; Teh-Ia Huo
Journal:  Sci Rep       Date:  2018-10-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.